ISO 10993-1: Risk Management Process for Evaluation and Testing
ISO 10993 Preclinical Testing for Medical Devices/
WESHIN INSPECTION TECH CO., LTD_

The Cornerstone of Medical Device Compliance: In-depth Analysis of ISO 10993-1

 

In the process of medical device R&D and regulatory submission (such as Taiwan TFDA, US FDA, or EU MDR), safety assessment is the most critical step to obtaining market clearance. ISO 10993-1 is the globally recognized core standard for the biological evaluation of medical devices.
 

What is ISO 10993-1?

 

ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process," is not just a checklist of tests, but a risk management framework. Its primary goal is to ensure that materials do not cause potential harm to the human body by evaluating biological responses upon contact.
 

Two Key Dimensions of Evaluation

 

According to ISO 10993-1, the evaluation strategy depends on two characteristics of the device:

  1. Nature of Contact: Categorized into surface-contacting (e.g., skin, mucosal membranes), external communicating (e.g., blood path), and implant devices.

  2. Contact Duration:

    • A - Limited: Less than or equal to 24 hours

    • B - Prolonged: 24 hours to 30 days.

    • C - Permanent: Greater than 30 days

 

Why is This Evaluation Critical for Your Product?

 

  1. Regulatory Mandate: Almost all medical devices with direct or indirect human contact must submit biocompatibility reports compliant with ISO 10993-1.

  2. Tiered Evaluation Strategy: By prioritizing Chemical Characterization to assess material risk, unnecessary animal testing can be reduced, adhering to 3Rs principles.

  3. Mitigating Post-Market Risk: Identifying toxicity or irritation early in the R&D phase prevents the massive losses associated with product recalls due to safety issues.
     

Professional Services by Weshin Inspection Tech

 

With a deep background in toxicological testing and molecular biology, Weshin provides one-stop consultation from preclinical stages to regulatory submission:

  • Customized Testing Protocols: We design the most streamlined and compliant testing suites based on your product’s unique characteristics and contact type.

  • Expert Data Interpretation: We assist clients in analyzing biological test results and authoring Biological Evaluation Reports (BER).

  • Synergistic Technical Expertise: Leveraging our strengths in primer design and precision analysis, we also offer microscopic cellular response evaluations for high-end medical devices.


Click to Pay
BACK